Biome Achieves Record Sales Revenue in FY24
Filed with ASX · · 5 pages · English
Watch Biome Australia's latest callBiome Australia (ASX:BIO) Q1 2026 Earnings Call · Replay · Oct 22, 2025Read the transcript of Biome Australia (ASX:BIO) Q1 2026 Earnings Call● Pharmacy retail scan sales of Activated Probiotics (Pharmacy RRP), from May 2023 through to May 2024, reached ~$12m and is the number-one brand for growth in the category Microbiome health company Biome Australia Limited (ASX: BIO) (‘Biome’ or ‘the company’) is pleased to announce unaudited full-year sales revenue of ~$13m for FY24, representing 80% growth vs PCP ($7.23m FY23). Biome’s H2 unaudi
Earlier from Biome Australia
- Biome expects to exceed FY24 forecast
- International Market Update and Health Canada approvals
- Non-Deal Investor Presentation April 2024
- First Quarter of Positive Underlying Cash Flow
- Biome Releases First Half FY2024 Results
Later from Biome Australia
- Biome shares three-year revenue target
- Clinically Proven Cholesterol Reducing Probiotic Launched
- Financial Year 2024 Key Results
- Amended Preliminary Financial Report
- Company Presentation
Follow Biome Australia into a list and get an email when it puts out news.
Follow Biome Australia